BHVN logo

BHVN Biohaven Ltd.

New York Stock Exchange · Biotechnology · Healthcare

$14.38
+0.70 (+5.12%)

Biohaven Ltd. operates as a biopharmaceutical firm actively engaged in clinical trials. Its primary objective is to advance innovative treatments for disorders affecting the nervous and immune systems, with the potential to transform current medical interventions.

Market Cap: $2.17Bwww.biohaven.com

Price

No data yet.

Social Signal Score

50
5d
50
1 mentions
30d
50
1 mentions
60d
50
1 mentions
90d
50
1 mentions
news: 1

Revenue

$0.00
$0.00$30.98M$61.96M$92.93M
Mar 2017Jun 2026

Analyst Estimates

FY2025
$-6.61
$-7.30$-5.37
7 analysts
FY2026
$-3.21
$-3.36$-2.99
9 analysts
FY2027
$-2.62
$-3.20$-2.07
10 analysts

Consensus estimates, not results. Via Financial Modeling Prep.

Company Profile

CEO
Vladimir Coric
Sector
Healthcare
Industry
Biotechnology
Employees
274
Beta
3.16
Country
US
Piotroski score
2 / 9 (Weak)
Altman Z-score
-9.74
www.biohaven.com